Pfizer : Unaudited Results – Quarter ended December 31, 2025

Pfizer Limited

The Capital, 1802/1901,

Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051.

Tel : [phone] Fax : [phone]

February 9, 2026

The Corporate Relationship Dept. BSE Limited

1stFloor, P.J.Towers Dalal Street, Fort Mumbai - 400 001

Scrip Code: 500680

The Listing Dept.

The National Stock Exchange of India Ltd. Exchange Plaza, 5thFloor, Plot No. C/1,

G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051

Scrip Symbol: PFIZER

Dear Sirs / Madam,

Sub: Outcome of Board Meeting - Unaudited Financial Results for the quarter and nine months ended December 31, 2025.

Ref.: Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025, which were approved by the Board of Directors of the Company at their Meeting held today i.e., February 9, 2026, that commenced at 3.00 p.m. and concluded at 4.45 p.m.

Also please find enclosed herewith the Limited Review Report issued by the Statutory Auditors, B S R & Co. LLP, in respect of the said Unaudited Financial Results.

Request you to please take the above on record. Thanking you,

Yours truly,

For Pfizer Limited

Prajeet

Nair

Prajeet Nair

Digitally signed by Prajeet Nair

Date: 2026.02.09

19:14:20 +05'30'

Director - Corporate Services & Company Secretary

CIN: L24231MH1950PLC008311

Email ID: [e-mail] Website: https://www.pfizerltd.co.in

B S R & Co. LLP

Chartered Accountants

14th Floor. Central B Wing and North C Wing Nesco IT Park 4, Nesco Center

Western Express Highway

Goregaon (East), Mumbai - 400 063, India Telephone: [phone]

rax: +e1 tz2) 6257 1010

Limited Review Report on unaudited financial results of Pfizer Limited for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Dieclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Pfizer Limited

1. We have reviewed the accompanying Statement of unaudited financial results of Pfizer Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Acoounting Standard 34 "interim Financial Reporfing" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended gListing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Reviat of Interim Financial Information Performed by the Independent Auditor of the Enid, issued by the Institute of Chartered Accountams of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and othar review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.: 101248W/W-100022

Mumbai

09 February 2026

Sreeja Marar

Partner Membership No.: 111410 UDIN:26111410JDNYDT2380

Pfizer Limited

The Capital. 1 802/1901, Plot No. C - 70. G Block. Bandra Kurla Compiex.

Bandra (East). MumDai 400 051.

Tel : [phone] Fax : •91 22 2654 0274

zer

Statement of Unaudited Financial Results for the Quarter and Nine months ended 31 December 2025

E

(I in crore excapt egmfngs per ahare'

	PaztTculars	3 months ended 31/12/Z025	Proceeding 3 months ended 30/09/2025	Corresponding 3 months ended 31/12/202g	Year to date figures for line months ended 3*/IZ/ZOZ5	¥ear to date flgUres for Nine mcntks ended 3*/*/2D2B	Previous year ended 3t/03/2025
		Unaudited	Unaudlted	Unaudited	Unaudlted	unaudlted	Audlted
1	Income
	fal Revenue from operations			537.99	1.890.42	1,689.M	2,281.35
		38.21	4185	42.76	147.23	12?.6?	172.25
	Total income	6M.24	684.19	580.75	2,037.65	1,817.11	2,4S3.60
2	Expenses
	Raj Cost of materials consumed	6778	70.0C	6731	226.47	2017€	272.34
	(b) Purchases of stock-in-trade	145.15	222.27	104.99	490.70	373.23	512.75
	[c} Changes in inventory of finished goods, work-in-progress and
	stock-in-trade	z2.84	(63.32	24.26	(S3.22)	33.04	25.36
	(d) Employee Benefits expense	100.30	94,67	9629	290.79	288.42	372.33
	(e) Finance costs	1.99	2. 1?	1.51	7.37	$.72	8.41
	(f) Depreciation and amortization expense	14.26	14.28	14.80	42.95	44.35	60.79
	(g) Other expenses	91.77	89.78	991°	267.54	280.32	359.34
3	Total expenses Profit before tax and exceptional items (1 - 2)	433.09 250.15	428.87 zss.zy	40&31 172.44	1,272.60 ?65.OS	1,226.82 S90.29	1,610.32
4	Exceptionalitems (Refer Note 4 & 5)	(58.20)			(58.20)		172.BJ
5	Profit before tax {3 + 4)	191.95	255.37		706.55	S90.2S	1,016.%
6	Tax expense
	(a) Current tax	58@0	65.49	50.1C	190.88	165.M
	(b) Deferred tax	(7.89)	0.86	t526	(6.64)	(11.41
7	Net profit for the year (5 - 6)	141.84		127.60	522.61	436.66	767.60
8	Other comprehensive income
	(a) Items that will not be reclassified subsequently to profit or loss	2.51	(1.22	{0.72	0.06	{2.15	0.95
	(b) Income tax reJated to items that will not be reclassified to profit or loss	(0.64)	0.31	0.19	(0.0)	0.54	10.25
	Other compnehens1ve tncome, net of taxes	1.67	(0-91)	(0.54	0.04	(1.61)	0,74
9	Totat comprehensive Income for the period / year (7 + 8}		288.11	127.06		435.05
IC	Paid-up eqtJity share capital (Face value per share t10)	417	457S	45.75	45.7?	45.75	45.75
11	Other equity						4,171.6E
12	Earnings per share - Basic and Diluted (of T10/- each) # Computed on the basis of net profit for the year	31.01	41.32	27.8t	114.24	95.44	167.7g

# Earnings per share Bas‹c and Diluted before Exceptional irems 'Not annualised

C1N:

Email ID:

4Q.42

41.32

27.89

95.44

136.46

NOTES:

1. The above financial results were reviewed by the Audit Committee and thereaher approved by the Board of Directors at their meeting held on February 09, 2026.

2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time).

3. The financial results for the quarter and nine months ended Oecei›Jber 81, 2025 have been subject to limited review by the statutory auditors of the Compa»v The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company's website - »' vv"jJtiz'il!rt.‹ O.ii,

4. Exceptional items of R58.20 crore for the quarter and nine months ended December 31, 2025 include:

   1. During the quarter, the Company has entered into an excIus ve Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands of the Company, vi2., Corex Dx, Corex LS, Dolonex, and Neksium. The charge of R39.58 crore includes personnel separation cost of field force and marketing teams as a result of the said arrangement and also includes personnel separation cost for other support funttions.

   2. Effective 21 November 2025, the Government of India has consolidated several existing labour laws into a unified framework consisting of four Labour Codes, collectively known as the 'New Ldbour Codes'. The Company has carried out an assessment based on the best available information and legal opinion, which has resulted in increase in the provision for employee benefits by 718.62 crore. The incremental impact is primarily due to change in wage definition. Considering the materiality and non-recurring nature of this impact, the Company has accounted SuCh incremental impact under Exceptional items in the financial results for the quarter and nine months ended December 31, 2025. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.

5. Exceptional Items for the Year ended March 31, 20Z5 relates to Net gain ofX172.81 crore (net of carrying value of R31.75 crore and cost to sell - Premium and other chargesR59.84 crore, net of recovery) on account of assignment of Lease of MIDC Land and Sale of Building constructed on such land.

6. The Compa v has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.

7. The Company does not have any subsidiary company or associate company or joint venture company as at December 31, 2025.

For Pfizer Limited

February 09, 2026

Meenakshi Nevatia Managing Director